Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

558 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fine-Tuning Approach for Segmentation of Gliomas in Brain Magnetic Resonance Images with a Machine Learning Method to Normalize Image Differences among Facilities.
Takahashi S, Takahashi M, Kinoshita M, Miyake M, Kawaguchi R, Shinojima N, Mukasa A, Saito K, Nagane M, Otani R, Higuchi F, Tanaka S, Hata N, Tamura K, Tateishi K, Nishikawa R, Arita H, Nonaka M, Uda T, Fukai J, Okita Y, Tsuyuguchi N, Kanemura Y, Kobayashi K, Sese J, Ichimura K, Narita Y, Hamamoto R. Takahashi S, et al. Among authors: hata n. Cancers (Basel). 2021 Mar 19;13(6):1415. doi: 10.3390/cancers13061415. Cancers (Basel). 2021. PMID: 33808802 Free PMC article.
TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H, Matsushita Y, Machida R, Yamasaki K, Hata N, Ohno M, Yamaguchi S, Sasayama T, Tanaka S, Higuchi F, Iuchi T, Saito K, Kanamori M, Matsuda KI, Miyake Y, Tamura K, Tamai S, Nakamura T, Uda T, Okita Y, Fukai J, Sakamoto D, Hattori Y, Pareira ES, Hatae R, Ishi Y, Miyakita Y, Tanaka K, Takayanagi S, Otani R, Sakaida T, Kobayashi K, Saito R, Kurozumi K, Shofuda T, Nonaka M, Suzuki H, Shibuya M, Komori T, Sasaki H, Mizoguchi M, Kishima H, Nakada M, Sonoda Y, Tominaga T, Nagane M, Nishikawa R, Kanemura Y, Kuchiba A, Narita Y, Ichimura K. Arita H, et al. Among authors: hata n. Acta Neuropathol Commun. 2020 Nov 23;8(1):201. doi: 10.1186/s40478-020-01078-2. Acta Neuropathol Commun. 2020. PMID: 33228806 Free PMC article.
Pediatric Glioma: An Update of Diagnosis, Biology, and Treatment.
Funakoshi Y, Hata N, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Takigawa K, Mizoguchi M. Funakoshi Y, et al. Among authors: hata n. Cancers (Basel). 2021 Feb 12;13(4):758. doi: 10.3390/cancers13040758. Cancers (Basel). 2021. PMID: 33673070 Free PMC article. Review.
Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study.
Aoki T, Kagawa N, Sugiyama K, Wakabayashi T, Arakawa Y, Yamaguchi S, Tanaka S, Ishikawa E, Muragaki Y, Nagane M, Nakada M, Suehiro S, Hata N, Kuroda J, Narita Y, Sonoda Y, Iwadate Y, Natsumeda M, Nakazato Y, Minami H, Hirata Y, Hagihara S, Nishikawa R. Aoki T, et al. Among authors: hata n. Int J Clin Oncol. 2021 Dec;26(12):2205-2215. doi: 10.1007/s10147-021-02028-1. Epub 2021 Sep 29. Int J Clin Oncol. 2021. PMID: 34586548 Free PMC article.
The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.
Natsume A, Arakawa Y, Narita Y, Sugiyama K, Hata N, Muragaki Y, Shinojima N, Kumabe T, Saito R, Motomura K, Mineharu Y, Miyakita Y, Yamasaki F, Matsushita Y, Ichimura K, Ito K, Tachibana M, Kakurai Y, Okamoto N, Asahi T, Nishijima S, Yamaguchi T, Tsubouchi H, Nakamura H, Nishikawa R. Natsume A, et al. Among authors: hata n. Neuro Oncol. 2023 Feb 14;25(2):326-336. doi: 10.1093/neuonc/noac155. Neuro Oncol. 2023. PMID: 35722822 Free PMC article. Clinical Trial.
Liquid Biopsy for Glioma Using Cell-Free DNA in Cerebrospinal Fluid.
Otsuji R, Fujioka Y, Hata N, Kuga D, Hatae R, Sangatsuda Y, Nakamizo A, Mizoguchi M, Yoshimoto K. Otsuji R, et al. Among authors: hata n. Cancers (Basel). 2024 Feb 29;16(5):1009. doi: 10.3390/cancers16051009. Cancers (Basel). 2024. PMID: 38473369 Free PMC article. Review.
Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
Funakoshi Y, Hata N, Takigawa K, Arita H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Sako A, Umehara T, Yoshitake T, Togao O, Hiwatashi A, Yoshimoto K, Iwaki T, Mizoguchi M. Funakoshi Y, et al. Among authors: hata n. Cancer Med. 2021 May;10(10):3177-3187. doi: 10.1002/cam4.3860. Epub 2021 Apr 10. Cancer Med. 2021. PMID: 33838014 Free PMC article.
Clinicopathologic analysis of pineal parenchymal tumors of intermediate differentiation: a multi-institutional cohort study by the Kyushu Neuro-Oncology Study Group.
Yamashita S, Takeshima H, Hata N, Uchida H, Shinojima N, Yokogami K, Nakano Y, Sakata K, Fudaba H, Enomoto T, Nakahara Y, Ujifuku K, Sugawara K, Iwaki T, Sangatsuda Y, Yoshimoto K, Hanaya R, Mukasa A, Suzuki K, Yamamoto J, Negoto T, Nakamura H, Momii Y, Fujiki M, Abe H, Masuoka J, Abe T, Matsuo T, Ishiuchi S; Kyushu Neuro-Oncology Study Group. Yamashita S, et al. Among authors: hata n. J Neurooncol. 2023 Apr;162(2):425-433. doi: 10.1007/s11060-023-04310-w. Epub 2023 Apr 13. J Neurooncol. 2023. PMID: 37052748
558 results